公开(公告)号：US20170283878A1

公开(公告)日：2017-10-05

申请号：US15376598

申请日：2016-12-12

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Sarah K.C. CHEUNG ,  Po-Kai CHUANG ,  Tsui-Ling HSU

IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/50

CPC classification number: C12Q1/6886 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y204/01 ,  G01N33/5073 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2333/70585 ,  G01N2333/70596 ,  G01N2333/91097 ,  G01N2405/10 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/52

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

公开(公告)号：US20180106780A1

公开(公告)日：2018-04-19

申请号：US15729317

申请日：2017-10-10

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Sarah R. Hanson ,  Masaaki SAWA

IPC: G01N33/50 ,  G01N33/533

CPC classification number: G01N33/5005 ,  G01N33/5008 ,  G01N33/533 ,  G01N2400/00

Abstract: Methods for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates are disclosed. Alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars are incorporated into cellular glycoconjugates. Chemical probes comprising an azide group and a visual or fluorogenic probe and used to label alkyne-derivatized sugar-tagged glycoconjugates are disclosed. Chemical probes bind covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and are visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA, confocal microscopy, and mass spectrometry.

公开(公告)号：US20160289340A1

公开(公告)日：2016-10-06

申请号：US15011543

申请日：2016-01-30

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Yi-Wei LOU ,  Chih-Wei LIN ,  Shih-Chi YEH ,  Chung-Yi WU ,  Han-Chung WU ,  Han-Chung WU

IPC: C07K16/44

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Abstract translation: 本文公开了包含与globo H，SSEA3和SSEA-4结合的抗体或其抗原结合片段的药物组合物及其使用方法。 使用的方法包括但不限于癌症治疗和诊断。 本公开的抗体可以结合某些癌细胞表面。 本文公开的抗体的示例性靶标可以包括癌，例如脑，皮肤，骨，肺，乳腺，食道，胃，肝，胆管，胰腺，结肠，肾，子宫颈，卵巢和/或前列腺癌中的那些。

公开(公告)号：US20190269227A1

公开(公告)日：2019-09-05

申请号：US16415411

申请日：2019-05-17

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Sarah R. HANSON ,  Masaaki SAWA

IPC: A45F3/14 ,  A41F9/02 ,  A45F5/02 ,  A45F3/00 ,  A45F3/10

Abstract: The present disclosure relates to a method for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates. The disclosed method incorporates alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars into a cellular glycoconjugate. A chemical probe comprising an azide group and a visual probe or a fluorogenic probe is used to label the alkyne-derivatized sugar-tagged glycoconjugate. In one aspect, the chemical probe binds covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and is visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA or confocal microscopy, and mass spectrometry.

公开(公告)号：US20160102151A1

公开(公告)日：2016-04-14

申请号：US14798312

申请日：2015-07-13

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Yi-Wei LOU ,  Chih-Wei LIN ,  Shih-Chi YEH ,  Chung-Yi WU ,  Han-Chung WU

IPC: C07K16/44 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2400/00 ,  G01N2405/10 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.